Bristol-Myers Squibb Co
XHAM:BRM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
36.735
58.24
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
112.5B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.5B AUD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Bristol-Myers Squibb Co
Glance View
Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Bristol-Myers Squibb Co is 33.5%, which is above its 3-year median of 25.6%.
Over the last 3 years, Bristol-Myers Squibb Co’s Operating Margin has increased from 25.5% to 33.5%. During this period, it reached a low of 23.2% on Mar 31, 2024 and a high of 33.5% on Sep 30, 2025.